Related Experiment Videos

[Infections with drug resistant bacteria and their treatment methods--PRSP infections]

H Kuroki1

  • 1Department of Pediatrics, Chiba University School of Medicine.

Rinsho Byori. the Japanese Journal of Clinical Pathology
|May 11, 2000
PubMed

Insights

Penicillin-resistant Streptococcus pneumoniae (PRSP) is a growing threat in infections. Treatment options for PRSP are limited, necessitating careful antimicrobial selection and judicious use.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Streptococcus pneumoniae is a primary cause of respiratory and systemic infections.
  • Increasing isolation of Penicillin-resistant Streptococcus pneumoniae (PRSP) complicates treatment strategies.

Observation:

  • Penicillin resistance in S. pneumoniae is a significant clinical challenge.
  • Therapeutic options for PRSP infections are becoming more difficult to manage.

Findings:

  • Ampicillin and amoxicillin are recommended for intermediate strains in respiratory infections.
  • Panipenem is a potential first-line treatment for systemic PRSP infections.
  • Vancomycin administration is also a consideration for PRSP treatment.

Implications:

  • Judicious antimicrobial use is crucial to prevent the spread of multi-resistant strains.
  • Physical therapy may be recommended in certain cases of S. pneumoniae infections.
  • Effective management of PRSP requires strategic therapeutic choices and antimicrobial stewardship.

Related Concept Videos